Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (PHAT) is a clinical-stage biopharmaceutical company advancing innovative treatments through its FDA-approved therapy vonoprazan. This page aggregates all essential updates related to PHAT's progress in gastrointestinal medicine, providing investors and medical professionals with a centralized news source.
Discover official announcements covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated selection emphasizes transparency, offering neutral reporting on financial results, research breakthroughs, and market expansion efforts without investment bias.
Key focus areas include vonoprazan's commercialization progress, new therapeutic applications under investigation, and analyses of PHAT's role in evolving acid suppression therapies. Content is maintained to reflect the company's position at the forefront of GI treatment innovation.
Bookmark this page for streamlined access to Phathom's verified announcements. Regular updates ensure stakeholders stay informed about developments shaping the company's trajectory in biopharmaceutical markets.
Phathom Pharmaceuticals (Nasdaq: PHAT) will present real-world data for VOQUEZNA® (vonoprazan) at Digestive Disease Week® (DDW) in San Diego from May 3-6, 2025. The presentation includes two posters analyzing real-world treatment patterns and patient characteristics of VOQUEZNA-treated GERD patients.
VOQUEZNA is the first FDA-approved treatment of its kind for adults with Non-Erosive GERD and all severities of Erosive Esophagitis. The company will host a Product Theater and maintain booth #1743 at the conference.
Key events include:
- VOQUEZNA Product Theater on May 4, 2025 (12:15 PM PT)
- Independent Medscape CME Symposia on May 4 (6:00 PM PT)
- Real-world data poster presentations on May 5 (12:30 PM PT)
Phathom Pharmaceuticals (NASDAQ: PHAT) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 1, 2025, at 8:00 am EDT. The company will host a live webcast accessible through their investor relations website, with a recording available for 90 days afterward.
Phathom specializes in gastrointestinal disease treatments and markets VOQUEZNA® (vonoprazan) tablets in the United States. Their product lineup includes treatments for:
- Non-Erosive GERD heartburn relief in adults
- Healing and maintenance of Erosive GERD in adults
- H. pylori infection treatment through VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®
Phathom Pharmaceuticals (PHAT) has appointed Ted Schroeder to its Board of Directors. Schroeder brings over 30 years of experience leading biopharmaceutical companies, with expertise in building commercial organizations, launching new therapies, and guiding companies through strategic milestones.
Board Chairman Michael Cola highlighted Schroeder's appointment comes at a pivotal period for Phathom, particularly as the company focuses on unlocking the full potential of VOQUEZNA®. Schroeder's operational and commercial expertise is expected to support Phathom's commercial momentum in delivering first-in-class therapies for gastrointestinal diseases.
Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will engage in a fireside chat on Tuesday, April 8th, 2025, at 10:15 am ET.
The conference, scheduled to run from April 7-10, 2025, will also feature one-on-one meetings with company management. A live webcast and archived recording of the event will be accessible through the Events & Presentations section of Phathom's website, with the recording remaining available for 90 days after the meeting.
Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of novel treatments for gastrointestinal (GI) diseases.
Phathom Pharmaceuticals (Nasdaq: PHAT) has announced the approval of inducement awards connected to Steven Basta's appointment as President and CEO. The compensation package includes:
- A non-qualified stock option to purchase 1,085,000 shares, with 25% vesting on April 1, 2026, and the remainder vesting in 36 monthly installments
- 360,000 performance stock units tied to stock price hurdles
- 180,000 performance stock units (with potential 200% target earnings) linked to revenue targets through December 31, 2027
The company, focused on gastrointestinal disease treatments, markets VOQUEZNA® tablets for heartburn and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment.
Phathom Pharmaceuticals (NASDAQ: PHAT) has announced a significant leadership change with the appointment of Steven Basta as President, CEO, and Board member, effective immediately. Basta replaces Terrie Curran, who is stepping down from her positions for personal reasons after five years of leadership.
The company, which focuses on developing and commercializing novel treatments for gastrointestinal (GI) diseases, views this transition as an opportunity to accelerate commercial growth. Chairman Michael Cola expressed confidence in Basta's extensive commercial expertise and track record in developing novel treatments.
Under this transition, Phathom aims to expand opportunities for their product VOQUEZNA® and enhance shareholder value. The new CEO emphasized his commitment to unlocking VOQUEZNA's full potential in addressing unmet needs in GI disease treatment.
Phathom Pharmaceuticals (NASDAQ: PHAT) has announced a partnership with actor and comedian Kenan Thompson to launch the 'GERD IS NO JOKE' campaign, raising awareness about gastroesophageal reflux disease (GERD) and their treatment VOQUEZNA® (vonoprazan).
Thompson, the longest-running SNL cast member, reveals his personal struggle with Non-Erosive GERD and his successful treatment with VOQUEZNA, the first FDA-approved potassium competitive acid blocker (PCAB) for both types of GERD. The campaign aims to reach over 65 million Americans living with GERD through multiple channels, including broadcast television, streaming platforms, and social media.
VOQUEZNA is approved for adults for:
- Relief of heartburn associated with Non-Erosive GERD
- Treatment of all severities of Erosive Esophagitis
- Relief of related heartburn
Phathom Pharmaceuticals (PHAT) reported strong Q4 and full year 2024 results for VOQUEZNA®, its gastrointestinal treatment. The company achieved $55.3 million in net revenues for 2024, including $29.7 million in Q4 (81% increase from Q3).
Key highlights include:
- Over 300,000 filled prescriptions launch-to-date (110% increase since last report)
- More than 20,000 healthcare providers have prescribed VOQUEZNA
- Commercial coverage reaching 120+ million lives (80% of U.S. commercial lives)
- Q4 2024 net loss of $74.5 million compared to $79.6 million in Q4 2023
The company plans to initiate a Phase 2 EoE trial in Q2 2025 and has launched a direct-to-consumer campaign. Cash position stands at $297.3 million as of December 31, 2024, with an additional $100 million available under term loan.
Phathom Pharmaceuticals (NASDAQ: PHAT) has announced it will host a live webcast on Thursday, March 6, 2025, at 8:30 am ET to present its fourth quarter and full year 2024 financial results along with a business update.
The company specializes in developing and commercializing treatments for gastrointestinal diseases. Their key product is vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) marketed in the US as VOQUEZNA®. The treatment is approved for heartburn associated with Non-Erosive GERD in adults, healing and maintenance of Erosive GERD, and comes in TRIPLE PAK® and DUAL PAK® combinations for H. pylori infection treatment.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
